Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01974258
Title Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

melanoma

Advanced Solid Tumor

colorectal cancer

Therapies

Onartuzumab + Vemurafenib

Cobimetinib + Onartuzumab

Cobimetinib + Onartuzumab + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Los Angeles California 90025 United States Details
Sarasota Florida 34232 United States Details
Detroit Michigan 48201 United States Details
Canton Ohio 44718 United States Details
Oklahoma City Oklahoma 73104 United States Details
Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field